A COVID-19 antibody treatment has now been approved by the Food and Drug Administration (FDA).
Accordingly, the agency authorized the treatment for those who are unvaccinated or are immunocompromised, including those with autoimmune diseases, HIV patients, cancer patients, and organ transplant recipients, who have been or are at risk of being exposed to the coronavirus even after being fully vaccinated.
This is the first time an injectable coronavirus antibody treatment has been approved for use to prevent COVID-19 after someone has been exposed to the virus, according to NBC News.
FDA said that the treatment should not be considered a vaccine substitute, but it can help protect people after exposure to COVID-19 by preventing severe illness.
Monoclonal antibody treatments can help prevent severe disease, hospitalization, and death, but the use of the drugs has remained limited because they typically had to be administered through an IV infusion and need to be given within 10 days after COVID-19 symptoms begin.
Now, the treatment can be administered as an injection, with the first dose being administered within 96 hours of exposure.
According to the FDA’s expanded authorization, individuals must be unvaccinated or immunocompromised at high risk of severe COVID-19. They must have been in close contact with someone who has tested positive to receive the preventive treatment.